A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions.
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Ipilimumab (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2017 According to a Transgene media release, first patient in this trial has been treated at the Leon Berard Cancer Center in Lyon, France. First readouts is expected towards the end of 2017.
- 20 Jan 2017 Status changed from active, no longer recruiting to recruiting.
- 10 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.